QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
NASDAQ:SNCE

Science 37 (SNCE) Stock Price, News & Analysis

$5.75
+0.02 (+0.35%)
(As of 03/12/2024)
Today's Range
$5.73
$5.75
50-Day Range
$4.74
$5.75
52-Week Range
$3.73
$12.96
Volume
49,100 shs
Average Volume
43,227 shs
Market Capitalization
$34.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
SNCE stock logo

About Science 37 Stock (NASDAQ:SNCE)

Science 37 Holdings, Inc. engages in patient-centric clinical trial activities in North Carolina. Its platform enables modern and digital approaches to clinical research, including the patient and trial investigators, nurses, coordinators, and sponsors, standardize evidence generation, and harmonize data. The company's platform also provides specialized networks of patient communities, telemedicine investigators, mobile nurses, remote coordinators, and connected devices for orchestrating clinical trials; and extensive configuration to support virtually any phase of clinical study and therapeutic area. In addition, the company licenses its proprietary hosted technology platform to various life science institutions. It serves large and mid-sized pharmaceutical companies, contract research organizations, academic institutions, and biotech companies. Science 37 Holdings, Inc. was founded in 2014 and is based in Research Triangle Park, North Carolina. As of March 11, 2024, Science 37 Holdings, Inc. operates as a subsidiary of eMed, LLC.

SNCE Stock Price History

SNCE Stock News Headlines

Claim Your Complimentary Bitcoin Reward
Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.
eMed commences tender offer for Science 37
Science 37 Initiates Cost-Cutting, Workforce Reduction Plan
Science 37 Holdings Inc SNCE
This consistently signaled gains of 453%... 610%... and even 1036%...
It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.
Science 37 just downgraded at Craig-Hallum, here's why
Science 37 Shares Rise on Deal to Be Acquired
NDRA, LITM and SNCE among mid-day movers
Science 37 Receives Top Honors in Everest PEAK Matrix®
See More Headlines
Receive SNCE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Science 37 and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Health Information Services
Sub-Industry
N/A
Current Symbol
NASDAQ:SNCE
Fax
N/A
Employees
460
Year Founded
N/A

Profitability

Net Income
$-50,990,000.00
Net Margins
-206.86%
Pretax Margin
-207.00%

Debt

Sales & Book Value

Annual Sales
$60.26 million
Book Value
$16.70 per share

Miscellaneous

Free Float
5,564,000
Market Cap
$34.33 million
Optionable
Not Optionable
Beta
0.55
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Mr. David Coman (Age 54)
    CEO & Director
    Comp: $796.13k
  • Ms. Christine A. Pellizzari J.D. (Age 56)
    Chief Legal & Human Resources Officer and Secretary
    Comp: $521.58k
  • Ms. Darcy Forman (Age 48)
    Chief Delivery Officer
    Comp: $550.58k
  • Mr. Mike Zaranek (Age 53)
    Chief Financial Officer
  • Irena Lambridis
    VP and Head of Quality Assurance & Compliance
  • Ms. Margie Gimbel Kooman
    Vice President of Marketing & Communications
  • Mr. Drew Bustos
    Chief Strategy & Marketing Officer
  • Mr. Jonathan Cotliar M.D. (Age 52)
    Chief Medical Officer
    Comp: $486.6k
  • Mr. Michael Shipton (Age 52)
    Chief Commercial Officer
  • Mr. Tyler Van Horn
    VP of Corporate Strategy & Chief of Staff

SNCE Stock Analysis - Frequently Asked Questions

Should I buy or sell Science 37 stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Science 37 in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" SNCE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SNCE, but not buy additional shares or sell existing shares.
View SNCE analyst ratings
or view top-rated stocks.

How have SNCE shares performed in 2024?

Science 37's stock was trading at $5.34 on January 1st, 2024. Since then, SNCE stock has increased by 7.7% and is now trading at $5.75.
View the best growth stocks for 2024 here
.

Are investors shorting Science 37?

Science 37 saw a drop in short interest in the month of February. As of February 29th, there was short interest totaling 13,800 shares, a drop of 56.9% from the February 14th total of 32,000 shares. Based on an average trading volume of 52,900 shares, the short-interest ratio is presently 0.3 days. Currently, 0.2% of the company's stock are short sold.
View Science 37's Short Interest
.

When did Science 37's stock split?

Shares of Science 37 reverse split on Friday, December 8th 2023. The 1-20 reverse split was announced on Friday, December 8th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, December 8th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Who are Science 37's major shareholders?

Science 37's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Kent Lake Capital LLC (4.67%), Glynn Capital Management LLC (2.96%), Russell Investments Group Ltd. (2.84%), Vanguard Group Inc. (2.69%), Vanguard Group Inc. (2.69%) and Citadel Advisors LLC (1.13%).
View institutional ownership trends
.

How do I buy shares of Science 37?

Shares of SNCE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SNCE) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners